Koyfin Home > Directory > Health Care > Amag Pharmaceuticals > Long-term Debt / Equity

Amag Pharmaceuticals Long-term Debt / Equity Chart (AMAG)

Amag Pharmaceuticals annual/quarterly Long-term Debt / Equity from 2014 to 2020.
  • Amag Pharmaceuticals Long-term Debt / Equity for the quarter ending June 06, 2020 was $122m a 52.89% increase of 65m year over year
  • Amag Pharmaceuticals Long-term Debt / Equity for the last 12 months ending June 06, 2020 was $122m a 52.89% increase of 65m year over year
  • Amag Pharmaceuticals Annual Long-term Debt / Equity for 2019 was $106m a 66.70% increase of 71m from 2018
  • Amag Pharmaceuticals Annual Long-term Debt / Equity for 2018 was $35m a -163.20% decrease of -58m from 2017
  • Amag Pharmaceuticals Annual Long-term Debt / Equity for 2017 was $93m a -11.13% decrease of -10m from 2016
Other Ratios Metrics:
  • Amag Pharmaceuticals Total Debt / Capital for the quarter ending September 09, 2018 was $27m a -79.63% decrease of -21m year over year
  • Amag Pharmaceuticals Other Liabilities for the quarter ending December 12, 2018 was $1m a -3,223.97% decrease of -46m year over year
  • Amag Pharmaceuticals Total Debt / Equity for the quarter ending September 09, 2018 was $37m a -153.66% decrease of -56m year over year
View Chart On Koyfin

Quarterly AMAG Long-term Debt / Equity Data

06/2020$122m
03/2020$114m
12/2019$106m
09/2019$58m
06/2019$55m
03/2019$44m
12/2018$35m
09/2018$34m
06/2018$99m
03/2018$97m

Annual AMAG Long-term Debt / Equity Data

2019$106m
2018$35m
2017$93m
2016$103m
2015$105m
2014$100m